Evotec SE stock (DE0005664809): After Nasdaq delisting, investors eye Q1 2025 update and strategy reset

Evotec SE is in a transition phase that combines weaker quarterly figures with a strategic portfolio shift and a streamlined listing structure after leaving Nasdaq. The Hamburg-based biotech company reported lower revenues in the first quarter of 2025 and confirmed its full-year outlook, while its shares continue to trade in Frankfurt and on Xetra, according to a Q1 update published on 05/14/2025 on the company website and a delisting notice dated 06/18/2024 from the US exchange Evotec investor information as of 05/14/2025 and Nasdaq company overview as of 06/18/2024.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

Evotec SE: core business model

Evotec SE positions itself as a drug discovery and development partner for pharmaceutical and biotech companies, focusing on early-stage research and preclinical development. The group operates a platform model, combining wet-lab biology and chemistry with data analytics and, increasingly, artificial intelligence to accelerate the identification and optimization of new therapeutic candidates, as outlined in its company profile updated in 2025 Evotec company profile as of 03/12/2025.

Instead of bringing its own drugs to late-stage clinical trials at scale, Evotec seeks to participate in value creation via milestones and potential royalties from partnered projects. The company collaborates with large pharma groups, mid-sized biotechs and academic institutions, focusing on areas such as neurology, metabolic diseases, immunology and oncology. This partnership-centric model is designed to balance steady service revenues with upside from successful drug candidates, according to the firm’s strategic overview published in 2024 Evotec strategy update as of 11/20/2024.

Evotec runs multiple research sites across Europe and North America, including facilities in Germany, France, the United Kingdom and the United States. These locations give the group access to academic clusters and pharma hubs, helping to attract international clients and talent. For US investors, the company’s presence in key American biotech centers means that operational and commercial exposure extends beyond its German listing venue.

Main revenue and product drivers for Evotec SE

The bulk of Evotec’s revenues comes from fee-for-service research contracts, where clients pay for access to the company’s scientists, laboratories and technology platforms. This includes target identification, screening, hit-to-lead optimization and early preclinical work. In addition, Evotec earns milestone payments when collaboration programs hit predefined development or regulatory stages, and it may receive royalties if partnered drugs reach the market, according to its 2024 annual report published on 03/26/2025 Evotec annual report 2024 as of 03/26/2025.

Therapeutic focus areas include central nervous system disorders, kidney disease, metabolic indications such as diabetes, and certain cancer types. Evotec also invests in so-called co-owned pipeline assets, where it shares in development costs and potential future returns. This approach can raise earnings volatility because milestone and royalty streams are inherently less predictable than service revenues, but it also offers upside if partnered compounds progress successfully through clinical trials, as illustrated in the pipeline update released in late 2024 Evotec pipeline overview as of 12/10/2024.

Technology-wise, Evotec emphasizes the integration of high-throughput screening, induced pluripotent stem cell platforms and AI-driven analytics to handle complex biological data. This combination is designed to differentiate its offering in a competitive contract research landscape and to strengthen long-term partnerships with large pharmaceutical clients, particularly those seeking external innovation to complement internal R&D efforts.

Recent financial performance and Nasdaq delisting

Evotec’s Q1 2025 results, published on 05/14/2025, showed that group revenues declined versus the prior-year period, while adjusted EBITDA remained under pressure amid continued investments in platform capabilities and pipeline programs. Management reiterated guidance for the 2025 financial year, targeting revenue growth and an improvement in profitability over the full period, according to the quarterly statement available on the investor relations site Evotec Q1 2025 statement as of 05/14/2025.

Alongside the operational development, Evotec reshaped its capital market presence. The company announced a voluntary delisting of its American Depositary Shares from Nasdaq in 2024, arguing that trading volumes in the US were relatively limited compared with Xetra and that the cost and complexity of a dual listing no longer justified the benefits. The delisting became effective in mid-2024, while the ADSs continue to be accessible in the United States on the over-the-counter market, according to Nasdaq’s corporate events information published on 06/18/2024 Nasdaq delisting notice as of 06/18/2024.

For US-based investors, the move means that Evotec is now primarily accessible via its Frankfurt listing and that liquidity is concentrated in Europe. The company remains subject to European regulatory requirements, including reporting standards under German and EU rules, which shape the timing and content of financial disclosures relevant for cross-border investors.

Why Evotec SE matters for US investors

Even without a primary US listing, Evotec has significant commercial exposure to the American healthcare and biotech ecosystem. Many of its major partners are US-based pharmaceutical or biotechnology groups, and the company operates research facilities on American soil. This means that trends in US drug pricing, FDA regulatory pathways and biotech funding conditions can influence the pace and scale of Evotec’s collaborations, as highlighted in its 2024 annual report discussion of regional revenue exposure Evotec annual report 2024 as of 03/26/2025.

Currency fluctuations between the euro and the US dollar also play a role, given that a material portion of collaboration revenues is denominated in dollars. For US investors evaluating foreign-listed biotech service companies, the combination of operational exposure to the US healthcare market and listing in the eurozone creates an additional FX layer that can amplify or dampen local share-price performance relative to the underlying business trends.

In addition, Evotec’s focus on off-balance-sheet value through milestone and royalty agreements with US partners can make the stock a way to participate indirectly in the broader American biotech pipeline. However, the timing of these potential inflows is uncertain, so fundamental analysis often centers on the stability of service revenues, the diversity of collaboration partners and the progress of a selected set of late-stage partnered programs.

Conclusion

Evotec SE is navigating a period of mixed signals: a softer revenue profile in early 2025 and ongoing investments in technology platforms, combined with a refocused capital market setup after its Nasdaq exit. For internationally oriented investors, the company offers exposure to a diversified portfolio of partnered drug discovery projects and to structural demand for outsourced R&D services. At the same time, the stock remains sensitive to collaboration dynamics, milestone timing and broader biotech sentiment in both Europe and the United States. Thorough due diligence on partner quality, pipeline maturity and financial resilience therefore remains essential when assessing the risk-return profile of this German-listed biotech group.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.